{"id":57095,"date":"2026-02-13T18:47:48","date_gmt":"2026-02-13T10:47:48","guid":{"rendered":"https:\/\/flcube.com\/?p=57095"},"modified":"2026-05-08T14:58:35","modified_gmt":"2026-05-08T06:58:35","slug":"novocures-optune-pax-wins-fda-approval-for-pancreatic-cancer-zai-lab-china-rights-in-play","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=57095","title":{"rendered":"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play"},"content":{"rendered":"\n

Novocure Ltd.<\/strong> (NASDAQ:\u202fNVCR<\/a><\/strong>), Zai Lab Ltd.’s<\/strong> (NASDAQ:\u202fZLAB<\/a>, HKG:\u202f9688<\/a><\/strong>) Swiss oncology partner<\/strong>, announced FDA clearance<\/strong> for Optune Pax<\/strong>, its portable Tumor Treating Fields (TTFields) device<\/strong>, for locally advanced pancreatic cancer<\/strong> in combination with gemcitabine and nab-paclitaxel<\/strong>. The Phase III PANOVA-3 data<\/strong> demonstrated significant overall survival improvement<\/strong> (16.2 vs. 14.2 months) and pain-free survival benefit<\/strong> (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care<\/strong> in this high-mortality malignancy<\/strong>.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Technology Developer<\/strong><\/td>Novocure Ltd. (NASDAQ:\u202fNVCR; Swiss-based)<\/td><\/tr>
China Partner<\/strong><\/td>Zai Lab Ltd. (NASDAQ:\u202fZLAB; HKG:\u202f9688)<\/td><\/tr>
FDA-Cleared Device<\/strong><\/td>Optune Pax \u2013 Portable TTFields delivery system<\/td><\/tr>
Indication<\/strong><\/td>Locally advanced pancreatic cancer + gemcitabine\/nab-paclitaxel<\/td><\/tr>
Mechanism<\/strong><\/td>Tumor Treating Fields (TTFields)<\/strong> \u2013 Non-invasive, wearable electric field arrays<\/td><\/tr>
Pivotal Data<\/strong><\/td>Phase III PANOVA-3 study<\/td><\/tr>
Zai Lab Rights<\/strong><\/td>Greater China TTFields development and commercialization<\/strong> (licensed September\u202f2018)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence \u2013 PANOVA-3 Phase III<\/h2>\n\n\n\n
Endpoint<\/th>Optune Pax + Chemotherapy vs. Chemotherapy Alone<\/th>Clinical Significance<\/th><\/tr><\/thead>
Overall Survival (OS)<\/strong><\/td>16.2 months vs. 14.2 months<\/strong> (ITT)<\/td>2-month survival benefit<\/strong>; meaningful in pancreatic cancer<\/strong> (median OS historically <12 months)<\/td><\/tr>
Pain-Free Survival<\/strong><\/td>15.2 months vs. 9.1 months<\/strong><\/td>6.1-month improvement<\/strong>; quality-of-life enhancement<\/strong><\/td><\/tr>
Quality of Life<\/strong><\/td>Trend toward improvement<\/strong><\/td>Patient-reported outcomes support tolerability advantage<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Technology Profile & Strategic Positioning<\/h2>\n\n\n\n
Feature<\/th>Optune Pax Specification<\/th>Competitive Differentiation<\/th><\/tr><\/thead>
Delivery<\/strong><\/td>Portable, wearable device<\/strong><\/td>Home-based therapy<\/strong>; continuous treatment<\/strong> without hospitalization<\/td><\/tr>
Mechanism<\/strong><\/td>Electric fields disrupt cancer cell mitosis<\/strong><\/td>Non-invasive<\/strong>; no systemic toxicity<\/strong>; combination with chemotherapy<\/strong><\/td><\/tr>
Patient Compliance<\/strong><\/td>>18 hours daily wear<\/strong> required<\/td>Integrated support program<\/strong>; real-world adherence monitoring<\/strong><\/td><\/tr>
Pancreatic Cancer Context<\/strong><\/td>Gemcitabine\/nab-paclitaxel backbone<\/strong><\/td>First FDA-approved device<\/strong> for locally advanced disease<\/strong>; extends chemotherapy efficacy<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Zai Lab China Strategy<\/h2>\n\n\n\n
Milestone<\/th>Status<\/th>Strategic Value<\/th><\/tr><\/thead>
2018 Licensing Agreement<\/strong><\/td>Zai Lab secured Greater China TTFields rights<\/strong><\/td>Early-stage partnership<\/strong> with innovative oncology technology<\/strong><\/td><\/tr>
Glioblastoma Approval<\/strong><\/td>NMPA approved May\u202f2020<\/strong><\/td>First TTFields indication in China<\/strong>; commercial infrastructure established<\/strong><\/td><\/tr>
Pancreatic Cancer Pathway<\/strong><\/td>FDA approval enables NMPA submission<\/strong><\/td>PANOVA-3 China cohort data<\/strong> supports regulatory filing<\/strong>; 2026-2027 approval anticipated<\/strong><\/td><\/tr>
Commercial Synergy<\/strong><\/td>Existing hospital relationships<\/strong> (neuro-oncology)<\/td>Expand to gastrointestinal oncology<\/strong>; pancreatic cancer specialist access<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Expansion Potential<\/h2>\n\n\n\n
Factor<\/th>Strategic Analysis<\/th><\/tr><\/thead>
Pancreatic Cancer Burden<\/strong><\/td>>120,000 new cases annually in China<\/strong>; 5-year survival <10%<\/strong>; urgent need for novel therapies<\/strong><\/td><\/tr>
TTFields Market Expansion<\/strong><\/td>Glioblastoma (approved)<\/strong> \u2192 Pancreatic cancer (FDA 2026)<\/strong> \u2192 Mesothelioma, NSCLC<\/strong> (pipeline)<\/td><\/tr>
Zai Lab Oncology Portfolio<\/strong><\/td>Optune complements Zejula (PARP), Qinlock (KIT), NUZYRA (tetracycline)<\/strong>; device + drug combination expertise<\/strong><\/td><\/tr>
Reimbursement Strategy<\/strong><\/td>Innovative medical device pathway<\/strong> in China; NRDL negotiation<\/strong> for cancer supportive care<\/strong> category<\/td><\/tr>
Global Alignment<\/strong><\/td>FDA approval validates technology<\/strong>; supports Zai Lab partnership valuation<\/strong> and ex-China rights discussions<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding Optune Pax NMPA approval timelines in China, Zai Lab’s pancreatic cancer commercialization strategy, and TTFields market expansion in solid tumors. Actual results may differ due to regulatory review delays, physician adoption of device-based oncology therapy, and reimbursement negotiation outcomes for medical devices in China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.’s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[16,869,1321,868,1322,15,413],"class_list":["post-57095","post","type-post","status-publish","format-standard","hentry","category-company","category-medical-device","tag-cancer","tag-hkg-9688","tag-nasdaq-nvcr","tag-nasdaq-zlab","tag-novocure","tag-product-approvals","tag-zai-lab"],"yoast_head":"\nNovocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.'s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=57095\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play\" \/>\n<meta property=\"og:description\" content=\"Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.'s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=57095\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-13T10:47:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-08T06:58:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57095#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57095\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play\",\"datePublished\":\"2026-02-13T10:47:48+00:00\",\"dateModified\":\"2026-05-08T06:58:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57095\"},\"wordCount\":469,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"HKG: 9688\",\"NASDAQ: NVCR\",\"NASDAQ: ZLAB\",\"Novocure\",\"Product approvals\",\"Zai Lab\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57095#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57095\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=57095\",\"name\":\"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-13T10:47:48+00:00\",\"dateModified\":\"2026-05-08T06:58:35+00:00\",\"description\":\"Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.'s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57095#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=57095\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=57095#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play - Insight, China's Pharmaceutical Industry","description":"Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.'s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=57095","og_locale":"en_US","og_type":"article","og_title":"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play","og_description":"Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.'s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.","og_url":"https:\/\/flcube.com\/?p=57095","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-13T10:47:48+00:00","article_modified_time":"2026-05-08T06:58:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=57095#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=57095"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play","datePublished":"2026-02-13T10:47:48+00:00","dateModified":"2026-05-08T06:58:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=57095"},"wordCount":469,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","HKG: 9688","NASDAQ: NVCR","NASDAQ: ZLAB","Novocure","Product approvals","Zai Lab"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=57095#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=57095","url":"https:\/\/flcube.com\/?p=57095","name":"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-13T10:47:48+00:00","dateModified":"2026-05-08T06:58:35+00:00","description":"Novocure Ltd. (NASDAQ:\u202fNVCR), Zai Lab Ltd.'s (NASDAQ:\u202fZLAB, HKG:\u202f9688) Swiss oncology partner, announced FDA clearance for Optune Pax, its portable Tumor Treating Fields (TTFields) device, for locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The Phase III PANOVA-3 data demonstrated significant overall survival improvement (16.2 vs. 14.2 months) and pain-free survival benefit (15.2 vs. 9.1 months), positioning TTFields as a new standard-of-care in this high-mortality malignancy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=57095#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=57095"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=57095#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novocure\u2019s Optune Pax Wins FDA Approval for Pancreatic Cancer; Zai Lab China Rights in Play"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=57095"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57095\/revisions"}],"predecessor-version":[{"id":57096,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/57095\/revisions\/57096"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=57095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=57095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=57095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}